Do analysts rate OSRH or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer ERNA or VBIO?

Ernexa Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 728.73%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Ernexa Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ERNA or VBIO more profitable?

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Ernexa Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics N/A -305.93% -169.86% Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Does the media refer more to ERNA or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.89 beat Valion Bio, Inc. Common Stock's score of 0.56 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CDIO or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CDIO or VBIO?

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 1.22 beat Valion Bio, Inc. Common Stock's score of 0.56 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate XTLB or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is XTLB or VBIO more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Do analysts rate CELZ or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELZ or VBIO more profitable?

Creative Medical Technology's return on equity of -86.52% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Valion Bio, Inc. Common Stock (VBIO) Competitors

$3.48 +0.75 (+27.47%)

As of 09/24/2026 04:00 PM Eastern

Compare

VBIO vs. OSRH, ERNA, CDIO, XTLB, and CELZ

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? Valion Bio, Inc. Common Stock's main competitors and comparable companies include OSR (OSRH), Ernexa Therapeutics (ERNA), Cardio Diagnostics (CDIO), XTL Biopharmaceuticals (XTLB), and Creative Medical Technology (CELZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valion Bio, Inc. Common Stock compare to OSR?

OSR (NASDAQ:OSRH) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than OSR. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 0 mentions for OSR. Valion Bio, Inc. Common Stock's average media sentiment score of 0.56 beat OSR's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
OSR	Neutral
Valion Bio, Inc. Common Stock	Positive

55.3% of OSR shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	5.05	-$27.06M	-$0.37	N/A
Valion Bio, Inc. Common Stock	$780K	3.97	-$8.88M	-$159.25	N/A

OSR has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Summary

OSR beats Valion Bio, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Ernexa Therapeutics (NASDAQ:ERNA) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Ernexa Therapeutics has a beta of 2.61, indicating that its stock price is 161% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580K	10.17	-$14.08M	-$14.35	N/A
Valion Bio, Inc. Common Stock	$780K	3.97	-$8.88M	-$159.25	N/A

70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Ernexa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.89 beat Valion Bio, Inc. Common Stock's score of 0.56 indicating that Ernexa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ernexa Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ernexa Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 728.73%. Given Ernexa Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Ernexa Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ernexa Therapeutics beats Valion Bio, Inc. Common Stock on 8 of the 15 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Cardio Diagnostics?

Cardio Diagnostics (NASDAQ:CDIO) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Cardio Diagnostics has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	571.87	-$6.50M	-$2.92	N/A
Valion Bio, Inc. Common Stock	$780K	3.97	-$8.88M	-$159.25	N/A

In the previous week, Cardio Diagnostics and Cardio Diagnostics both had 3 articles in the media. Cardio Diagnostics' average media sentiment score of 1.22 beat Valion Bio, Inc. Common Stock's score of 0.56 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardio Diagnostics has a beta of 2.28, meaning that its share price is 128% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Cardio Diagnostics beats Valion Bio, Inc. Common Stock on 8 of the 12 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

XTL Biopharmaceuticals has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	12.69	-$6.97M	-$0.64	N/A
Valion Bio, Inc. Common Stock	$780K	3.97	-$8.88M	-$159.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Valion Bio, Inc. Common Stock and 2 mentions for XTL Biopharmaceuticals. Valion Bio, Inc. Common Stock's average media sentiment score of 0.56 beat XTL Biopharmaceuticals' score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
Valion Bio, Inc. Common Stock	Positive

XTL Biopharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

XTL Biopharmaceuticals' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals beats Valion Bio, Inc. Common Stock on 7 of the 12 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Creative Medical Technology's return on equity of -86.52% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Creative Medical Technology has a beta of 2.04, suggesting that its share price is 104% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Creative Medical Technology has higher earnings, but lower revenue than Valion Bio, Inc. Common Stock. Creative Medical Technology is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	639.23	-$5.99M	-$2.07	N/A
Valion Bio, Inc. Common Stock	$780K	3.97	-$8.88M	-$159.25	N/A

In the previous week, Creative Medical Technology had 1 more articles in the media than Valion Bio, Inc. Common Stock. MarketBeat recorded 4 mentions for Creative Medical Technology and 3 mentions for Valion Bio, Inc. Common Stock. Creative Medical Technology's average media sentiment score of 1.38 beat Valion Bio, Inc. Common Stock's score of 0.56 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Creative Medical Technology beats Valion Bio, Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.21M	$3.98B	$7.32B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.02	14.00	274.41	25.76
Price / Sales	3.97	1,342.42	688.46	106.29
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.02	15.46	10.52	6.34
Net Income	-$8.88M	-$22.82M	$3.49B	$360.00M
7 Day Performance	64.15%	-1.96%	-0.94%	-0.16%
1 Month Performance	-12.45%	-8.13%	-4.24%	-4.08%
1 Year Performance	-95.34%	32.15%	16.38%	5.97%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.7251 of 5 stars	$3.48 +27.5%	N/A	-95.4%	$2.21M	$780K	N/A	10	Short Interest Decrease Gap Down High Trading Volume
OSRH OSR	0.2087 of 5 stars	$0.21 +15.8%	N/A	-60.6%	$7.20M	$1.81M	N/A	N/A	Gap Down
ERNA Ernexa Therapeutics	3.2475 of 5 stars	$3.91 -4.2%	$30.00 +667.3%	-87.2%	$6.66M	$580K	N/A	10
CDIO Cardio Diagnostics	1.2368 of 5 stars	$2.00 flat	N/A	-54.8%	$5.92M	$10K	N/A	1	Positive News Short Interest Decrease
XTLB XTL Biopharmaceuticals	0.4958 of 5 stars	$2.39 -4.4%	N/A	N/A	$5.91M	$450K	N/A	N/A	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. OSRH, ERNA, CDIO, XTLB, and CELZ

How does Valion Bio, Inc. Common Stock compare to OSR?

Summary

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to Cardio Diagnostics?

Summary

How does Valion Bio, Inc. Common Stock compare to XTL Biopharmaceuticals?

Summary

How does Valion Bio, Inc. Common Stock compare to Creative Medical Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. OSRH, ERNA, CDIO, XTLB, and CELZ

How does Valion Bio, Inc. Common Stock compare to OSR?

Do analysts rate OSRH or VBIO?

Does the media favor OSRH or VBIO?

Do insiders and institutionals hold more shares of OSRH or VBIO?

Which has higher earnings & valuation, OSRH or VBIO?

Which has more volatility & risk, OSRH or VBIO?

Is OSRH or VBIO more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to Ernexa Therapeutics?

Which has more risk & volatility, ERNA or VBIO?

Which has higher earnings and valuation, ERNA or VBIO?

Do insiders & institutionals hold more shares of ERNA or VBIO?

Is ERNA or VBIO more profitable?

Does the media refer more to ERNA or VBIO?

Do analysts prefer ERNA or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Cardio Diagnostics?

Which has stronger valuation & earnings, CDIO or VBIO?

Does the media favor CDIO or VBIO?

Is CDIO or VBIO more profitable?

Do institutionals and insiders have more ownership in CDIO or VBIO?

Which has more volatility & risk, CDIO or VBIO?

Do analysts prefer CDIO or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to XTL Biopharmaceuticals?

Which has better valuation & earnings, XTLB or VBIO?

Do analysts rate XTLB or VBIO?

Does the media prefer XTLB or VBIO?

Which has more volatility & risk, XTLB or VBIO?

Is XTLB or VBIO more profitable?

Do institutionals and insiders hold more shares of XTLB or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to Creative Medical Technology?

Is CELZ or VBIO more profitable?

Which has more risk & volatility, CELZ or VBIO?

Do institutionals and insiders have more ownership in CELZ or VBIO?

Do analysts rate CELZ or VBIO?

Which has stronger earnings and valuation, CELZ or VBIO?

Does the media favor CELZ or VBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools